The pooled analysis of these RCTs indicated that adult ITP patients who were treated with SYK and/or BTK inhibitors exhibited higher likelihood of achieving durable platelet response compared to those who only received placebo (RR 12.50; 95%CI: 3.99 – 39.18, p<0.0001, I2 = 0%, random-effect model) (Figure 2A) (Table 3). The gene discussed is BTK; the disease is autoimmune thrombocytopenic purpura.